Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists | Zendy

И. И. Дедов | Zendy; Н. Г. Мокрышева | Zendy; М. В. Шестакова | Zendy; Tatiana Vasil'evikonova | Zendy; Alexander Yur'evich Mayorov | Zendy; G. R. Galstyan | Zendy; M. Sh. Shamhalova | Zendy; В. О. Барышева | Zendy; Ametov As | Zendy; M. B. Antsiferov | Zendy; А. Yu. Babenko | Zendy; Т. П. Бардымова | Zendy; Ф. В. Валеева | Zendy; A. A. Vachugova | Zendy; Elena Grineva | Zendy; T. Yu. Demidova | Zendy; Т. П. Киселева | Zendy; M. A. Kunicyna | Zendy; T. V. Markova | Zendy; А. M. Mkrtumyan | Zendy; Н. А. Петунина | Zendy; L. A. Ruyatkina | Zendy; Vladimir V. Saluhov | Zendy; Л. А. Суплотова | Zendy; E. L. Hadarceva | Zendy; Yu. Sh. Halimov | Zendy

Open Access

Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists

Author(s) -

И. И. Дедов,

Н. Г. Мокрышева,

М. В. Шестакова,

Tatiana Vasil'evikonova,

Alexander Yur'evich Mayorov,

G. R. Galstyan,

M. Sh. Shamhalova,

В. О. Барышева,

Ametov As,

M. B. Antsiferov,

А. Yu. Babenko,

Т. П. Бардымова,

Ф. В. Валеева,

A. A. Vachugova,

Elena Grineva,

T. Yu. Demidova,

Т. П. Киселева,

M. A. Kunicyna,

T. V. Markova,

А. M. Mkrtumyan,

Н. А. Петунина,

L. A. Ruyatkina,

Vladimir V. Saluhov,

Л. А. Суплотова,

E. L. Hadarceva,

Yu. Sh. Halimov

Publication year - 2022

Publication title -

diabetes mellitus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.155

H-Index - 12

eISSN - 2072-0378

pISSN - 2072-0351

DOI - 10.14341/dm12873

Subject(s) - medicine , glycemic , type 2 diabetes mellitus , diabetes mellitus , pneumonia , disease , covid-19 , coronavirus , type 2 diabetes , viral pneumonia , intensive care medicine , insulin , endocrinology , infectious disease (medical specialty)

A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death. Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition. The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research